For concierge longevity practices · white-label reports

Cell-resolved biological age, without the hours of prep.

Your concierge patients pay for a report that takes hours to assemble by hand. CellWise turns one PBMC sample into an immune-age, senescence, and 12-Hallmarks profile: white-labeled, drafted automatically, and defensible against a sector full of unvalidated protocols.

See what it costs
✓ Founding pilot rate: $1,800 a patient ✓ White-labeled reports ✓ Founder pricing locked in
CellWise · Integrated Cellular Aging Profile
Immune age (sc-ImmuAging)
−3.2 yr
Senescence (SenMayo)
Low
Fastest-aging compartment
Naïve TExhausted CD8
Hallmarks flagged
3 of 12
Report drafted
auto
Simulator · tested in seconds
Rapamycin vs metformin, projected shift on this patient’s own molecular data
Grounded inreal population datapeer-reviewed researchlegacy single-cell technology
Founding Practitioner Pilot · fifty places

Up to five of your own patients at $2,095 $1,800 each, for Core Plus.

14% below standard Invoiced only for the ones you send.All in: kit, shipping and the blood draw.A sample that fails lab QC is not invoiced.Decide at the end of a 30-day review.
Per patient
$1,800

Core Plus, 14% below the $2,095 standard rate.

How many
One to five

Your own patients. Invoiced only for the ones you send.

Billing
On delivery, net 30

All in: collection kit, shipping and the phlebotomy draw. A failed QC sample is not invoiced.

Your decision
30-day review

Full module access from your last report, then decide whether to carry on.

Fifty founding places.Full pricing and terms
What it actually solves

What actually drains a concierge practice.

The work that scales worst with a premium roster, handled.

Hours of report prep per patient

Aggregating genomics, lipid panels, CGM, DEXA, and wearables into a custom longevity report is hours of physician time each visit. CellWise auto-drafts a white-labeled report from a single PBMC sample.

The concierge burnout that scales worst, gone

A sector full of unvalidated claims

Longevity is crowded with protocols that carry credibility and liability risk. CellWise anchors your read in three peer-reviewed frameworks: sc-ImmuAging, the 125-gene SenMayo panel, and the 12 Hallmarks of Aging.

Evidence you can stand behind in the room

Engagement between visits

Compliance slips without objective feedback. Longitudinal re-screens and assay-independent surveillance give patients a visible, molecular reason to stay the course.

Retention built on proof, not reminders
Rotates every few seconds. Hover to pause, click a headline to hold it.
Immune aging is a set of switches, read cell by cell.

The naive T-cell reserve, NK cytotoxicity and mitochondrial upkeep are programmes that drift long before anything is diagnosable. Real data from 26 reference donors with no known diagnosis: each column is one person, each row one gene in one cell type, coloured against people of the same sex.

Naive T-cell reserve off in 1 of 26 donors 26 reference donors, no known diagnosis. One column per person. Naive T-cell reserve ↓ switched off when the state is present CCR7 · CD4 T cells TCF7 · CD4 T cells TCF7 · CD8 T cells CCR7 · CD8 T cells CD28 · CD8 T cells NK cytotoxicity ↑ switched on when the state is present PRF1 · NK cells NKG7 · NK cells GZMB · NK cells Mitochondrial upkeep ↓ switched off when the state is present MFN2 · CD16 monocytes PINK1 · CD16 monocytes PINK1 · CD14 monocytes MFN2 · CD14 monocytes
Lower than reference Higher than reference not read Robust z-score of each gene in its cell type against same-sex reference donors (colour capped at ±5). Hover a square for the value.
  • Naive T-cell genes switching off (CCR7, TCF7, CD28) in CD4 and CD8 T cells: a thinning reserve, read per cell type rather than as one score.
  • Mitochondrial upkeep genes falling in monocytes: a cellular-energy signal a blood panel averages away.
  • Re-assay to see a switch move. The same genes, in the same cells, read again after an intervention.
Everything in the portal

Seven modules, one clinical workspace.

Health Analysis ReportIllustrative preview
SemaglutideGLP-1 receptor agonist · mapped with tirzepatide
Strong match
  1. Cell stateInnate inflammation on, in CD14 monocytes
  2. Genes4 move with the state, 1 against
  3. PathwayNF-κB and IL-1β
  4. MechanismLowered IL-1β and TNF in mononuclear cells in a randomised trial; pooled trials lower CRP. Human data
  5. Check firstA recent infection or vaccine, or hard exercise before the draw
In line with the state
IL1B ↑CXCL8 ↑NLRP3 ↑TNF ↑
Moving against it
CCL2 ↓

Read in this patient's CD14 monocytes against people of the same sex in the reference set.

Mechanism: human dataResponse: CellWise prediction, not yet validated
Module 01

Health Analysis Report

The clinical home base: risk-rated health domains, immuno-metabolic phenotyping, and mechanism-based peptide pairing, each call traced from cell state to genes, pathway and mechanism.

Clinicians see
Each peptide call explained: the cell state, the genes moving with it and against it, the pathway, the evidence tier and what to check first.
Licensees get
Report templates in your brand, under co-brand or white-label.
Biomarker AnalyticsIllustrative preview
S100A12
IL1B
ISG15
CCR7
TCF7
PRF1
HSPA5
same-sex reference rangethis patient
Module 02

Biomarker Analytics

The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.

Clinicians see
Every panel gene placed against the same-sex reference population, the outliers first.
Licensees get
The same views themed to your interface, or piped through the API.
Data ExplorerIllustrative preview
IL1B
Cell populationDirectionSignal
CD14 monocytes↑
CD16 monocytes↑
pDCs↑
CD4 T cells·
Module 03

Data Explorer

A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.

Clinicians see
Filter by gene, cell type or direction and see which populations carry each signal.
Licensees get
Gene-level data your scientific team can query, not just a PDF.
Clinical Scenario SimulatorIllustrative preview
HypothesisWhat if this patient starts a GLP-1 receptor agonist?
Re-running against this patient's data
Inflammasome tone
Insulin signalling
Interferon response
Module 04

Clinical Scenario Simulator

Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.

Clinicians see
Pose a clinical hypothesis against the patient's own data and re-run it in seconds.
Licensees get
A consult tool that keeps clinicians working inside your platform.
Outcomes & MonitoringIllustrative preview
BaselineLoadingMaintenance
Peptide-specific labWearable trend (HRV)
Module 05

Outcomes & Monitoring

Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.

Clinicians see
Peptide-specific labs and wearable trends tracked across dosing phases, between screens.
Licensees get
A monitoring loop that brings patients back to your menu between draws.
Cellular Aging ProfileIllustrative preview
Immune agewhich compartments are aging fastest, and which hallmarks drive it
Genomic instabilityTelomere attritionEpigenetic alterationProteostasisAutophagyNutrient sensingMitochondriaSenescenceStem-cell exhaustionCommunicationInflammationDysbiosis
Module 06

Cellular Aging Profile

Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.

Clinicians see
Immune age, senescence and the 12 hallmarks of aging from one PBMC sample.
Licensees get
A preventative-health line item you can list under your own name.
Longitudinal ScreeningIllustrative preview
IL1B · CD14 mono
↓
ISG15 · CD16 mono
·
CCR7 · CD4 T
↑
DDIT3 · NK
↓
Screen 1Screen 2
Module 07

Longitudinal Screening

Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.

Clinicians see
Re-assay and see exactly which genes moved, in which cells, since the last screen.
Licensees get
Re-assay built into the product, so the second test is part of the plan.
Hover or tap a module to stop on it. Previews are illustrative.
What the beta measured

Hours back, credibility up.

Reviewers converged on the same aging signal and the same intervention plan from a single sample, with no manual synthesis.

2–3 hrs
Of manual report synthesis replaced per patient, the concierge burnout that scales worst with roster size.
3
Peer-reviewed frameworks in one read: sc-ImmuAging, the 125-gene SenMayo panel, and the 12 Hallmarks of Aging.
1 sample
A single PBMC draw resolves which immune compartments are aging fastest, with no five-panel workup.
seconds
To test rapamycin vs metformin against the patient’s own molecular data in the Clinical Scenario Simulator.
<100
Patients on a concierge roster, and every one gets a validated, white-labeled profile instead of a hand-built PDF.
0
Repeat sequences needed to keep monitoring the plan between annual screenings.
From the review room

Same donor. Same aging signal. No hand-drafting.

“

The convergence of TLR9, IRF7, TLR7, and IFNG into a coherent narrative would take me 45–60 minutes to synthesize from raw scRNA-seq. The platform delivers it in a structured card.

Concierge Longevity MD
Beta review
“

A validated immune-age read from three peer-reviewed frameworks is exactly the credibility anchor this sector is missing.

Anti-Aging Physician
Beta review
“

Being able to simulate rapamycin against the patient’s actual expression before I write the plan changes the conversation in the room.

Regenerative Medicine MD
Beta review
◆ Illustrative, not testimonial. These show the kind of read the report supports, drafted from clinician personas during beta design rather than quoted from named practitioners. Reviews from the founding pilot will replace them.

Profile up to five patients, at the founding rate.

Join the founding pilot: up to five of your own patients at $1,800 each, 14% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to a limited cohort of concierge and longevity practices.